AMRN earnings: next report 2026-07-29, real EPS beat/miss history, analyst consensus Hold, P/E -8.47. Updated 2026-07-23.
Amarin (AMRN) Research Hub
Amarin (AMRN) trades on NASDAQ, IE in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 13.8 USD (-4.10%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.47, market cap 0.29B. This hub links to the full technical, earnings and options research available for AMRN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, IE |
| Last close | 13.8 USD (-4.10%) |
| 52-week range | 13.19 USD – 17.25 USD |
| Trend regime | Range |
| 14-day RSI | 42.4 (Bearish) |
| Trailing P/E | -8.47 |
| Market cap | 0.29B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-29 |
Available research for AMRN
Covered Call on AMRN: how it works, illustrative setup around the real 13.8 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AMRN: how it works, illustrative setup around the real 13.8 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AMRN: how it works, illustrative setup around the real 13.8 USD price, max profit/loss, breakeven and when to use it. Educational.
AMRN technical analysis: range, last 13.8 USD, RSI 42.4, 52w range 13.19 USD–17.25 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is AMRN in?
Amarin (AMRN) is classified under Healthcare (Biotechnology), listed on NASDAQ, IE.
Is AMRN in an uptrend or downtrend?
As of 2026-09-11, AMRN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AMRN's trailing P/E ratio?
AMRN's trailing P/E is -8.47, with a market cap of 0.29B. See the earnings research page for full valuation detail.
When does AMRN next report earnings?
AMRN is next scheduled to report earnings on 2026-07-29, with a consensus EPS estimate of -0.01 USD.